Combidex NDA accepted for FDA review

被引：0

|

作者：

不详

机构：

来源：

DRUG NEWS & PERSPECTIVES | 2000年 / 13卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：64 / 64

页数：1

相关论文

共 50 条

[41] FDA announces calcium review
不详
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1996, 96 (08) : 748 - 748
[42] An FDA review of sulfamethazine toxicity
Poirier, LA
Doerge, DR
Gaylor, DW
Miller, MA
Lorentzen, RJ
Casciano, DA
Kadlubar, FF
Schwetz, BA
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1999, 30 (03) : 217 - 222
[43] FDA to review phthalate risks
Franz, Neil
Chemical Week, 2002, 164 (28)
[44] DRUGS + FDA - REVIEW PROCEDURES
RAVDIN, IS
SCIENCE, 1964, 146 (364) : 12 - &
[45] Staccato Goes to FDA for Review
不详
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2010, 48 (02) : 47 - 47
[46] FDA Review Vouchers Reply
Kesselheim, Aaron S.
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (08): : 837 - 838
[47] FDA accepts Thymoglobulin for review
不详
DRUG NEWS & PERSPECTIVES, 1997, 10 (02) : 112 - 112
[48] NDA REVIEW TIME FOR NEW INDICATIONS OF ALREADY-APPROVED DRUGS
SPIVEY, RN
LASAGNA, L
TRIMBLE, AG
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 230 - 230
[49] A Letter to the FDA on Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA
Pluta, Paul L.
Poska, Richard
J. Validation Technol., 2020, 3
[50] The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars
Niazi, Sarfaraz K.
PHARMACEUTICALS, 2023, 16 (11)

← 1 2 3 4 5 →